The world’s first Phase 3 psilocybin clinical trial is about to commence
The landmark Phase 3 trial to explore the psychedelic’s ability to treat depression will enroll close to 1,000 participants and Compass is looking to U.S. FDA approval by the end of 2025.
The world’s first Phase 3 psilocybin clinical trial is about to commence Read more